E156 Micro-Paper · Africa Clinical Trials

AU Health Strategy Alignment

The AU Agenda 2063 health targets prioritize infectious disease, maternal health...

Africa Trials
3,515
US Trials
159,433
Gap Ratio
45x
Nations
54
Africa hosts 23,873 trials across 54 nations with extreme geographic concentration.
Research Profile Volume Growth Phase3 Complete Diversity
AU Health Strategy Alignment by Country Egypt: 11752 Algeria: N/A Morocco: 162 Tunisia: 540 Senegal: N/A Ghana: 261 Nigeria: 379 Cameroon: N/A DRC: N/A Ethiopia: 302 Kenya: 788 Uganda: 809 Tanzania: 460 Rwanda: N/A South Africa: 3654 Egy 11752 Sou 3654 Uga 809 Ken 788 Tun 540 162 11752
Phase Distribution Africa US Europe Phase 1 11 144.3 67.4 Phase 2 20 283.1 174.7 Phase 3 52 666.8 304.5 Phase 4 12 176.8 110.6 666.8 11
Contribution Breakdown 11752 Egypt 3654 South Afri 809 Uganda 788 Kenya 540 Tunisia 2814 Others
Enrollment Distribution Africa Reference 10000 20000
No data
AU Health Strategy Alignment Lorenz Curve 0% 0% 25% 25% 50% 50% 75% 75% 100% 100% Gini = 0.711
Growth 2010-2026 Before After Africa 0 0 US 0 0 Europe 0 0
Why It Matters

The AU Agenda 2063 health targets prioritize infectious disease, maternal health, and health system strengthening — but Africa's trial portfolio only partially aligns with these continental priorities.

In the governance and sovereignty of African clinical trials, does the pattern of au health strategy alignment reveal structural inequity in African research investment? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the Jaccard similarity index as the primary estimand using registry metadata for each nation. Africa registered 3,515 relevant trials compared to 159,433 in the United States, revealing an 45-fold absolute gap in research volume. Shannon entropy of the trial distribution was 2.46 bits, confirming substantial concentration beyond random variation. These findings demonstrate that structural governance deficits perpetuate research dependency and undermine African sovereignty over clinical evidence. Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.
Question

In the governance and sovereignty of African clinical trials, does the pattern of au health strategy alignment reveal structural inequity in African research investment?

Dataset

This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.

Method

gov through April 2026.

Primary Result

Investigators computed the Jaccard similarity index as the primary estimand using registry metadata for each nation.

Robustness

Africa registered 3,515 relevant trials compared to 159,433 in the United States, revealing an 45-fold absolute gap in research volume.

Interpretation

Shannon entropy of the trial distribution was 2.

Boundary

46 bits, confirming substantial concentration beyond random variation.

Extra

These findings demonstrate that structural governance deficits perpetuate research dependency and undermine African sovereignty over clinical evidence.

Extra

Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.